These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
200 related articles for article (PubMed ID: 35583125)
1. Demand and usage of unrelated donor products for allogeneic haematopoietic cell transplantation during the COVID-19 pandemic: A Canadian Blood Services Stem Cell Registry analysis. Allan DS; Green M; Morris G; Weiss J; Dibdin N; Mercer D; Seftel M Vox Sang; 2022 Sep; 117(9):1121-1125. PubMed ID: 35583125 [TBL] [Abstract][Full Text] [Related]
2. Meeting the Demand for Unrelated Donors in the Midst of the COVID-19 Pandemic: Rapid Adaptations by the National Marrow Donor Program and Its Network Partners Ensured a Safe Supply of Donor Products. Auletta JJ; Novakovich JL; Stritesky GL; Newman J; Fridy-Chesser ST; Hailperin K; Devine SM Transplant Cell Ther; 2021 Feb; 27(2):133-141. PubMed ID: 33830022 [TBL] [Abstract][Full Text] [Related]
3. Improved access to better HLA-matched hematopoietic cells for allogeneic transplant: analysis of donors and cord blood units selected for Canadian patients in 2018. Greco-Stewart V; Elmoazzen H; Morris G; Guo Y; Langdon C; Mercer D; Dibdin N; Allan DS Transfusion; 2020 Jul; 60(7):1508-1518. PubMed ID: 32319688 [TBL] [Abstract][Full Text] [Related]
4. Unrelated donor choices for allogeneic hematopoietic cell transplantation in Canada: an evaluation of factors influencing donor selection. Greco-Stewart V; Kiernan J; Killeen D; Haun S; Mercer D; Young K; Liwski RS; Allan DS Transfusion; 2018 Mar; 58(3):718-725. PubMed ID: 29277913 [TBL] [Abstract][Full Text] [Related]
5. The Effect of the COVID-19 Pandemic on Unrelated Allogeneic Hematopoietic Donor Collections and Safety. Parmar G; Allan DS; Morris G; Dibdin N; Ganz K; Mostert K; Paulson K; Petraszko T; Stevens N; Seftel MD Curr Oncol; 2023 Mar; 30(3):3549-3556. PubMed ID: 36975483 [TBL] [Abstract][Full Text] [Related]
6. Factors associated with registrant availability for unrelated adult donor hematopoietic stem cell donation: Analysis of the stem cell registry at Canadian Blood Services. Monaghan M; Yi QL; Green M; Campbell T; Weiss JT; Dibdin N; Mercer D; Elmoazzen H; Allan DS Transfusion; 2021 Jan; 61(1):24-28. PubMed ID: 33084098 [TBL] [Abstract][Full Text] [Related]
7. Allogeneic haemopoietic cell transplant services in Australia and New Zealand in the first year of the COVID-19 pandemic: a report from Australia and New Zealand transplant and cellular therapies. Othman J; Aarons D; Bajel A; Butler J; Doocey R; O'Brien T; Purtill D; Smith L; Wilcox L; Hamad N Intern Med J; 2023 Mar; 53(3):323-329. PubMed ID: 35833788 [TBL] [Abstract][Full Text] [Related]
8. HLA-haplotype redundancy and rareness in Canadian Blood Services' Stem Cell Registry and Cord Blood Bank: Novel metrics for optimizing utility. Bailey AJM; Blake J; Ganz K; Seftel MD; Allan DS Transfusion; 2023 Nov; 63(11):2114-2119. PubMed ID: 37750668 [TBL] [Abstract][Full Text] [Related]
9. Neither COVID-19, nor cryopreservation, prevented allogeneic product infusion: A report from the National Marrow Donor Program. Farhadfar N; Newman J; Novakovich J; Barten J; Ndifon ET; Oakes J; Cody M; Pham HP; Auletta JJ; Miller JP; Devine SM; Stefanski HE Front Immunol; 2022; 13():937900. PubMed ID: 36203566 [TBL] [Abstract][Full Text] [Related]
10. Outcomes of allogeneic haematopoietic stem cell transplantation from HLA-matched and alternative donors: a European Society for Blood and Marrow Transplantation registry retrospective analysis. Shouval R; Fein JA; Labopin M; Kröger N; Duarte RF; Bader P; Chabannon C; Kuball J; Basak GW; Dufour C; Galimard JE; Polge E; Lankester A; Montoto S; Snowden JA; Styczynski J; Yakoub-Agha I; Mohty M; Nagler A Lancet Haematol; 2019 Nov; 6(11):e573-e584. PubMed ID: 31477550 [TBL] [Abstract][Full Text] [Related]
11. Hematopoietic Cell Transplantation Trends and Outcomes in Canada: A Registry-Based Cohort Study. Seftel MD; Pasic I; Parmar G; Bucher O; Allan DS; Bhella S; Hay KA; Ikuomola O; Musto G; Prica A; Richardson E; Truong TH; Paulson K Curr Oncol; 2023 Nov; 30(11):9953-9967. PubMed ID: 37999143 [No Abstract] [Full Text] [Related]
12. Outcomes from unrelated donor hematopoietic stem cell transplantation. Perez LE Cancer Control; 2011 Oct; 18(4):216-21. PubMed ID: 21976240 [TBL] [Abstract][Full Text] [Related]
13. Optimizing Access to Unrelated Donors in Canada: Re-Examining the Importance of Donor Factors on Outcomes Following Hematopoietic Cell Transplantation. Parmar G; Seftel MD; Ganz K; Blake J; Holovati JL; Allan DS Curr Oncol; 2024 Apr; 31(5):2542-2551. PubMed ID: 38785471 [TBL] [Abstract][Full Text] [Related]
14. Allogeneic haematopoietic stem cell transplantation without a matched sibling donor: current options and future potential. Hwang WY; Ong SY Ann Acad Med Singap; 2009 Apr; 38(4):340-6. PubMed ID: 19434337 [TBL] [Abstract][Full Text] [Related]
16. Attrition at the final donor stage among unrelated haematopoietic stem cell donors: the British Bone Marrow Registry experience. Balassa K; Griffiths A; Winstone D; Li Y; Rocha V; Pawson R Transfus Med; 2019 Oct; 29(5):332-337. PubMed ID: 31209947 [TBL] [Abstract][Full Text] [Related]